|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100048318 |
|
最近更新日期: Date of Last Refreshed on: |
2021-07-05 19:47:44 |
|
注册时间: Date of Registration: |
2021-07-05 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
新型冠状病毒感染疾病(COVID-19)流行病学研究:基于病历记录的研究 |
|
Public title: |
Novel coronavirus infection disease (COVID-19): a epidemiology study based on medical records |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
新型冠状病毒感染疾病(COVID-19)流行病学研究 |
|
Scientific title: |
Novel coronavirus infection disease (COVID-19): a epidemiology study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张政 |
研究负责人: |
刘磊 |
|
Applicant: |
Zhang Zheng |
Study leader: |
Liu Lei |
|
申请注册联系人电话: Applicant telephone: |
+86 13927461302 |
研究负责人电话:
Study leader's |
+86 13510333313 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhangzheng1975@aliyun.com |
研究负责人电子邮件: Study leader's E-mail: |
liulei3322@aliyun.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
深圳市龙岗区布澜路29号 |
研究负责人通讯地址: |
深圳市龙岗区布澜路29号 |
|
Applicant address: |
29 Bulan Road, Longgang District, Shenzhen, Guangdong, China |
Study leader's address: |
29 Bulan Road, Longgang District, Shenzhen, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
深圳市第三人民医院 |
||
|
Applicant's institution: |
the Third People's Hospital of Shenzhen |
||
|
研究负责人所在单位: |
深圳市第三人民医院 |
||
|
Affiliation of the Leader: |
the Third People's Hospital of Shenzhen |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
深圳三院伦审科研字[2020-021-02]号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
深圳市第三人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Third People's Hospital of Shenzhen |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-07-13 00:00:00 | ||
|
伦理委员会联系人: |
刘老师 |
||
|
Contact Name of the ethic committee: |
Mr. Liu |
||
|
伦理委员会联系地址: |
深圳市龙岗区布澜路29号 |
||
|
Contact Address of the ethic committee: |
29 Bulan Road, Longgang District, Shenzhen, Guangdong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
深圳市第三人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
the Third People's Hospital of Shenzhen |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
深圳市龙岗区布澜路29号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
29 Bulan Road, Longgang District, Shenzhen, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
比尔及梅琳达·盖茨基金会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Bill and Melinda Gates Foundation |
||||||||||||||||||||||
|
研究疾病: |
新型冠状病毒肺炎(COVID-19) |
||||||||||||||||||||||
|
Target disease: |
Novel Coronavirus Pneumonia (COVID-19) |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
流行病学研究 |
||||||||||||||||||||||
|
Study type: |
Epidemilogical research |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
1. 开展 COVID-19 的流行病学研究,分析深圳 COIVD-19 人群流行病学、临床特征,为后续科学研究、技术开发和产品转化提 供基础;入组不同临床结局患者(轻症和重症),针对早期以及不同 阶段的外周全血、呼吸道、消化道标本。 2. 研究共感染和继发感染的病原谱,及其临床意义。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Carry out epidemiological research on COVID-19, analyze the epidemiology and clinical characteristics of Shenzhen COIVD-19 population, and provide the basis for subsequent scientific research, technology development and product transformation; enroll patients with different clinical outcomes (mild and mild) Severe disease), for early and different stages of peripheral whole blood, respiratory tract, digestive tract specimens. 2. To study the pathogen spectrum of co-infection and secondary infection and its clinical significance. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
有疫区接触史,或者家族聚集性发病,或者确诊患 者接触史;鼻咽拭子,或肺泡灌洗液,或肛拭子,新冠病毒核酸检测 阳性,并经市 CDC 确诊病例;境外输入的确诊病例;愿意签署知情 同意书. |
||||||||||||||||||||||
|
Inclusion criteria |
There is a history of contact with epidemic areas, or family clusters, or a history of contact with confirmed patients; nasopharyngeal swabs, or alveolar lavage fluid, or anal swabs, the new coronavirus nucleic acid test is positive, and confirmed by the city CDC Cases; confirmed cases imported from abroad; willing to sign informed consent |
||||||||||||||||||||||
|
排除标准: |
排除港澳台、外籍患者 |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclude Hong Kong, Macao, Taiwan, and foreign patients |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-06-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-07-05 00:00:00 至 To 1990-01-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
所有在深圳第三人民医院住院的新冠肺炎患者均被招募,无随机。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
No |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
通过ResMan共享,深圳市第三医院 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
IPD will be shared through ResMan |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集为病例记录表(Case Record Form, CRF),数据管理为电子采集和管理系统(Electronic Data Capture, EDC),ResMan |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection is a case record form (Case Record Form, CRF), data management is an electronic collection and management system (Electronic Data Capture, EDC), ResMan |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |